Cellestis

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Qiagen today said that it has completed the acquisition of all of the ordinary shares of Melbourne, Australia-based Cellestis for A$3.80 (US$4.04) per share.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Cellestis announced on Tuesday that the Supreme Court of Victoria in Australia has approved Qiagen's acquisition of its ordinary shares by way of a Scheme of Arrangement.

Shareholders overwhelmingly approved an amended proposal that will result in Qiagen paying around $374 million to acquire the Australian firm.

Qiagen's offer represents a premium of roughly 41 percent premium to the three-month volume-weighted average price of Cellestis' shares ending on April 1.

With the help of QuantiFeron tests in the first-line setting, Qiagen is hoping to improve the capabilities of its DNA and RNA diagnostics in preventing and profiling disease and delivering personalized care.

The deal provides Qiagen with access to Cellestis' QuantiFeron "pre-molecular" testing technology for detecting and monitoring disease.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.